Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Investigator Initiated Safety and Efficacy Clinical Trial of Combination Therapy of Intracutaneous GEN0101 With Intravenous Pembrolizmub in Patients Who Have Advanced Melanoma

NCT03818893 is registered in ClinicalTrials.gov with Osaka University as lead sponsor.

NCT NCT03818893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03818893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Investigator Initiated Safety and Efficacy Clinical Trial of Combination Therapy of Intracutaneous GEN0101 With Intravenous Pembrolizmub in Patients Who Have Advanced Melanoma
Lead sponsor
Osaka University
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2019
Completion date
June 30, 2022
Enrollment
46 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma